NIH Cuts Create a Lost Generation of Scientists
Trump administration attacks on the National Institutes of Health mean biomedical research will become less ambitious, less ...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...
Business Insider9d
Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX
Clearside Biomedical (CLSD) announced the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration relating to CLS-AX for the ...
Yahoo Finance9d
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical ... Phase 3 program during our upcoming earnings call later this month.” Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of ...